PMV Pharmaceuticals stock gains as biotech peers advance

Published on 09/05/2026 at 22:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PMV Pharmaceuticals stock in the biotechnology sector is trading higher, with investors watching recent clinical and financial benchmarks against a backdrop of active peers on Nasdaq.

PMVP, US7301281085, Illustration mit AI erstellt.

PMV Pharmaceuticals stock (ISIN US7301281085) is quoted at 1.29 USD as of September 4, 2026, giving the oncology-focused biotechnology company a market capitalization of 68.961 million USD according to Yahoo Finance.

Market context and peer comparison

According to market data compiled by Yahoo Finance, PMV Pharmaceuticals trades on Nasdaq in the biotechnology industry alongside peers such as Cogent Biosciences and Assembly Biosciences, with its 1.29 USD share price reflecting a significantly smaller capitalization than Cogent Biosciences, which stands at 6.032 billion USD.

The same overview lists PMV Pharmaceuticals with a market capitalization of 68.961 million USD as of September 4, 2026, implying that PMVP accounts for only about 1.1 percent of Cogent Biosciences' market value, underscoring the company’s small-cap profile in the current biotech landscape.

Volatility and price movement

Yahoo Finance quotes PMV Pharmaceuticals at 1.29 USD per share on September 4, 2026, with the stock up 4.03 percent on the day, showing that even modest absolute moves can translate into noticeable percentage swings for investors in a thinly traded biotech name.

For small-cap biotechnology stocks, daily moves of several percent are common, and the 4.03 percent gain at a 1.29 USD price level highlights how sensitive PMVP remains to relatively small changes in sentiment or trading volume.

Go deeper

More on PMV Pharmaceuticals stock

Background information and additional news on PMV Pharmaceuticals can be found in the topic overview at ad-hoc-news.de.

All articles on PMV Pharmaceuticals Investor Relations

Pipeline focus in precision oncology

PMV Pharmaceuticals focuses on developing precision oncology therapies targeting the p53 pathway, an important tumor suppressor mechanism that is frequently altered in cancer; this specialization positions the company in a niche of targeted cancer drug development where clinical data milestones can quickly influence the stock.

For investors, the value of PMV Pharmaceuticals will hinge on upcoming clinical readouts and regulatory interactions in this p53-focused pipeline, as progress or setbacks in trial results traditionally translate into sharp revaluations for early stage biotech names.

Stock price snapshot for retail investors

Based on the latest Nasdaq data summarized by Yahoo Finance for September 4, 2026, PMV Pharmaceuticals stock closed at 1.29 USD, and this level serves as the current reference point for retail investors following the name in the biotechnology segment.